Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cora N Sternberg

Showing results (131-140 of 357) with videos related to

Pageof 36
Sort By:
Oncology|October 16, 2015
Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061Linda Cerbone, Cora N Sternberg, Lisa Sengeløv, et al.
Annals of Nuclear Medicine|November 29, 2015
A case report of image-based dosimetry of bone metastases with Alpharadin ((223)Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-upMassimiliano Pacilio, Guido Ventroni, Bartolomeo Cassano, et al.
American Journal of Clinical Oncology|June 10, 2011
Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinomaManuela Schmidinger, Cezary Szczylik, Cora N Sternberg, et al.
European Urology|October 24, 2008
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risksHendrik Isbarn, Laurent Boccon-Gibod, Peter R Carroll, et al.
Cancer|April 28, 2009
Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinomaFabio Calabrò, Vito Lorusso, Gerardo Rosati, et al.
Cancer Treatment Reviews|April 11, 2021
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practicePetros Grivas, Neeraj Agarwal, Sumanta Pal, et al.
European Urology Focus|June 14, 2024
Artificial INtelligence to Support Informed DEcision-making (INSIDE) for Improved Literature Analysis in OncologyArnulf Stenzl, Andrew J Armstrong, Andrea Sboner, et al.
Future Oncology (London, England)|June 3, 2022
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trialMatthew R Smith, Maha Hussain, Fred Saad, et al.
The Lancet. Oncology|August 9, 2014
Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trialKarim Fizazi, Howard I Scher, Kurt Miller, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2016
Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trialsGiandomenico Roviello, Sandra Sigala, Shahneen Sandhu, et al.
Pageof 36

Showing results (131-140 of 357) with videos related to

Sort By:
Pageof 36
Oncology|October 16, 2015
Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061Linda Cerbone, Cora N Sternberg, Lisa Sengeløv, et al.
Annals of Nuclear Medicine|November 29, 2015
A case report of image-based dosimetry of bone metastases with Alpharadin ((223)Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-upMassimiliano Pacilio, Guido Ventroni, Bartolomeo Cassano, et al.
American Journal of Clinical Oncology|June 10, 2011
Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinomaManuela Schmidinger, Cezary Szczylik, Cora N Sternberg, et al.
European Urology|October 24, 2008
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risksHendrik Isbarn, Laurent Boccon-Gibod, Peter R Carroll, et al.
Cancer|April 28, 2009
Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinomaFabio Calabrò, Vito Lorusso, Gerardo Rosati, et al.
Cancer Treatment Reviews|April 11, 2021
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practicePetros Grivas, Neeraj Agarwal, Sumanta Pal, et al.
European Urology Focus|June 14, 2024
Artificial INtelligence to Support Informed DEcision-making (INSIDE) for Improved Literature Analysis in OncologyArnulf Stenzl, Andrew J Armstrong, Andrea Sboner, et al.
Future Oncology (London, England)|June 3, 2022
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trialMatthew R Smith, Maha Hussain, Fred Saad, et al.
The Lancet. Oncology|August 9, 2014
Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trialKarim Fizazi, Howard I Scher, Kurt Miller, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2016
Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trialsGiandomenico Roviello, Sandra Sigala, Shahneen Sandhu, et al.
Pageof 36